Armata Pharmaceuticals
ARMP
Armata Pharmaceuticals (ARMP) news
Recent news
Armata Pharmaceuticals - adult Phase 3 study for AP-SA02 expected to initiate in second half of 2026
AInvest Wire · Jul 13, 2026Armata Pharmaceuticals - FDA defers pediatric studies for AP-SA02 until adult Phase 3 data generated
AInvest Wire · Jul 13, 2026Armata Pharmaceuticals receives $2.5 million of additional non-dilutive award funding from the U.S. Department of Defense to support AP-SA02
AInvest Wire · Jun 23, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.